Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease
- PMID: 31561285
- PMCID: PMC6886305
- DOI: 10.1002/2211-5463.12734
Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease
Abstract
The effect of sodium-glucose cotransporter 2 inhibitor (SGLT2I) on nonalcoholic steatohepatitis (NASH) has been reported, but there are few studies on its effect on NASH-related renal injury. In this study, we examined the effect of SGLT2I using a novel medaka fish model of NASH-related kidney disease, which was developed by feeding the d-rR/Tokyo strain a high-fat diet. SGLT2I was administered by dissolving it in water of the feeding tank. SGLT2I ameliorates macrophage accumulation and oxidative stress and maintained mitochondrial function in the kidney. The results demonstrate the effect of SGLT2I on NASH-related renal injury and the usefulness of this novel animal model for research into NASH-related complications.
Keywords: Oryzias latipes; NASH; SGLT2 inhibitor; kidney; medaka disease model; renal disease.
© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).FEBS Open Bio. 2019 Feb 15;9(4):643-652. doi: 10.1002/2211-5463.12598. eCollection 2019 Apr. FEBS Open Bio. 2019. PMID: 30984539 Free PMC article.
-
Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.Biochem Biophys Res Commun. 2022 Mar 12;596:76-82. doi: 10.1016/j.bbrc.2022.01.086. Epub 2022 Jan 28. Biochem Biophys Res Commun. 2022. PMID: 35121372
-
Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.J Diabetes Res. 2020 Dec 27;2020:1682904. doi: 10.1155/2020/1682904. eCollection 2020. J Diabetes Res. 2020. PMID: 33457424 Free PMC article.
-
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28. Metabolism. 2019. PMID: 31672448 Review.
-
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. Kidney Int. 2018. PMID: 29735306 Review.
Cited by
-
Antioxidant Roles of SGLT2 Inhibitors in the Kidney.Biomolecules. 2022 Jan 16;12(1):143. doi: 10.3390/biom12010143. Biomolecules. 2022. PMID: 35053290 Free PMC article. Review.
-
Device implant based on poly (lactic acid) with vitamin E for vaccine delivery system in Tilapia: Study for biocompatibility and biodegradation.Fish Shellfish Immunol Rep. 2022 Jul 3;3:100060. doi: 10.1016/j.fsirep.2022.100060. eCollection 2022 Dec. Fish Shellfish Immunol Rep. 2022. PMID: 36419600 Free PMC article.
References
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84. - PubMed
-
- Lallukka S and Yki‐Jarvinen H (2016) Non‐alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 30, 385–395. - PubMed
-
- Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E et al (2007) Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496–506. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials